Institutional Investors

Showing 1998 articles
Business

Workday's Steep Slide: A Value Bet or Value Trap for Investors?

As the S&P 500 notches another year of robust gains, the concentrated nature of the rally has left some high-flying tech names like Workday in the dust. Hotchkis & Wiley's latest investor letter reveals the HR software giant was a significant drag on its value fund in Q4 2025, with shares down over 33% in a year. Against a backdrop of stretched market valuations, we examine whether this sell-off presents a compelling entry point or signals deeper troubles.

Business

Three Growth Stocks Poised to Outperform in a Volatile Market

Identifying companies with sustainable growth engines is a perennial challenge for investors. We analyze three firms—Vertiv, Ares Management, and Halozyme Therapeutics—that are expanding their competitive moats and delivering robust revenue growth, offering potential shelter in uncertain times.